Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors

#479

Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.

Aim(s): To test the efficacy and side effects of Everolimus in six patients with differentiated NET refractory to other therapies.

Materials and methods: Everolimus (10 mg/day; compassionate use) was administered until disease progression or unacceptable toxicity. Three patients had metastases of ileal neuroendocrine carcinoma; one of typical lung carcinoid; one of ovary carcinoid and one of pancreatic insulinoma.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ambrosio M, Guerra A, Lupo S, Bondanelli M, Sartori S,

Keywords: Everolimus, GEP-NET, efficacy, side effects,